LEU — LEU

One-line thesis

The only US-licensed HALEU producer sits at the mandatory processing chokepoint for every next-generation SMR and microreactor regardless of which reactor design wins -- making it picks-and-shovels for the entire domestic nuclear buildout.

Current state (2026-09-14)

Q2 2026 results (8-K/10-Q, 2026-08-05/06): revenue $176.1M vs $154.5M Q2 2025 (+14%); H1 revenue $252.8M vs $227.6M (+11%). GAAP net income $16.8M vs $28.9M Q2 2025 (-42%); H1 net income $26.8M vs $56.1M (-52%), driven by rising advanced-technology costs ($29.7M H1 2026 vs $6.3M H1 2025) and a $17.2M non-cash SG&A charge from reclassifying Board RSU grants to liability-classified awards. Technical Solutions segment swung to a $1.7M gross loss (from a $3.2M profit in Q2 2025), coinciding with DOE's disclosed intent not to further option the HALEU Operation Contract (see Risks). FY2026 guidance repeated at $450-500M revenue / $350-500M capital deployment. Combined backlog reached $4.5B (LEU segment $3.7B, of which ~$3.0B is contingent on Piketon capacity and $2.4B sits under definitive agreements; Technical Solutions $0.8B tied to the now-uncertain HOC). Under the $1.0B Nov-2025 ATM shelf, Centrus issued 278,114 shares for $55.0M gross ($54.2M net) in Q2 2026, leaving ~$554.5M of shelf capacity as of 2026-06-30 -- correcting this page's prior "drawn $0" claim.

Three private HALEU offtakers are now on record within a 13-week span, each structured around customer prepayments rather than disclosed price or volume: Oklo (Letter of Intent, 2026-06-18, up to five Aurora powerhouses, deliveries from 2029; no definitive agreement disclosed since) -- X-energy (definitive contract, 2026-08-06, supporting Xe-100 SMR and TRISO-X fuel deployments) -- Radiant (definitive contract, 2026-09-09, Kaleidos transportable microreactors, deliveries before decade-end). None discloses dollar value, volume, or duration.

Centrus priced a ~$500 million equity raise on 2026-09-10 (closed 2026-09-11): 500,000 Class A shares plus pre-funded warrants for up to 2,005,513 shares at $199.64 per share-equivalent, for ~$489 million net (424B5, 2026-09-11). Buyers also received, for no separate consideration, four series of common warrants on ~6.99 million further shares, struck at $226.86 (2028) to $362.98 (2031), ~$2 billion of exercise proceeds if all are exercised; cashless exercise is permitted and holders are capped at 4.99% ownership. Its ~$500M gross approaches the ~$554.5M of shelf capacity that remained at 2026-06-30, so remaining shelf headroom is limited absent a new registration; any Q3 2026 ATM issuance before the raise is not yet disclosed. Stated use of proceeds is general working capital / corporate purposes (technology investment, debt repayment, capex, potential acquisitions) -- Piketon is not named. The same filing discloses Centrus is in advanced discussions to acquire a domestic manufacturing supplier (~$160M FY2025 revenue) for ~$115-125M; no definitive agreement as of the filing date. The stock fell 7.8% on the announcement day and 6.5% on the closing day. Sector context: UBS cut NuScale to Sell the same week on SMR construction timelines, a demand-clock input for HALEU (a developer-specific call, not a Centrus signal). Internal re-audit, annotated 2026-09-14 with the ATM correction and the acquisition detail: project/research/leu_dilution_reaudit_2026-09-11.md. Thesis re-synthesized 2026-09-14 across 11 atoms: data/company_thesis_states/LEU.json.

Position

• T3-tranche position in the nuclear processing layer; established May 2026 and scaled later that month. STCG profile through ~May 2027 (hold-only window).
• Entry-add band refreshed 2026-06-10; band details are withheld while a staged accumulation plan is active.

Thesis (detailed)

Centrus holds the only US license to produce HALEU -- high-assay low-enriched uranium (enriched to 5-20% U-235), the fuel required by most next-generation reactor and microreactor designs. This is not a competitive moat that could be replicated quickly: the HALEU demonstration cascade at the American Centrifuge Plant in Piketon, Ohio took years to license under NRC special authorization, and no other domestic entity has cleared the regulatory path to HALEU production at scale.

The structural logic is straightforward. Mike already owns the mining layer (UUUU, URG, DNN). Those miners extract natural uranium -- but natural uranium at ~0.7% U-235 cannot power an advanced reactor. It must be enriched. HALEU is the enrichment grade that unlocks the SMR thesis. Without domestic HALEU supply, every US SMR program depends on foreign enrichment (historically Russia's TENEX, now being eliminated by the Prohibiting Russian Uranium Imports Act signed 2024). The cut runs both ways: Centrus itself sources more than half of its LEU-segment deliveries through 2027 from TENEX under DOE waivers, so the same policy wall that protects the HALEU moat is a supply risk to the legacy trading business (see Risks). LEU is the bridge from domestic mining to domestic deployment.

The DOE relationship is now a dated dependency, not a de-risker (revised 2026-06-10; the original "de-risks near-term revenue" framing did not survive the Q1 2026 10-Q). The HALEU Operation Contract funds cascade operation only through June 30, 2026 (Option 1a, funded $108.2M), and the FY2027 DOE budget proposal does not include funding for continued operation of the cascade; Option 1b requires a revised cost proposal before DOE will consider exercising it. The $900M HALEU Production Contract task order (selected January 5, 2026, with options up to an additional $170M) remains subject to negotiation of a definitive agreement, and Centrus lost the parallel $900M LEU Production task order to another bidder. Centrus is still revenue-generating -- not pre-revenue -- with FY2025 revenue of $448.7M and FY2026 guidance raised to $450-500M, which distinguishes it from every other nuclear watchlist name except BWXT. But the raised guidance itself assumes the $900M task order is finalized and funded. Monopoly license + picks-and-shovels positioning still hold; the government-revenue leg now carries two dated execution risks (see Risks and Triggers).

Analyst consensus at the 2026-05-14 writeup was Strong Buy with a 1Y target of $278 (vs. $213 writeup price). That snapshot predates the Q1 print and the June drawdown (~$148 on 2026-06-10) and needs re-verification before it carries weight in any decision. The thesis here is structural conviction and supply chain completion, not a 10x bet.

Recent catalysts (60-day rolling)

• 2026-09-10/11: ~$500M stock-plus-warrant offering closed (see Current state / Risks). Same filing (424B5) discloses advanced discussions to acquire a domestic manufacturing supplier (~$115-125M, target ~$160M FY2025 revenue); no definitive agreement as of the filing date.
• 2026-09-09: Definitive HALEU contract with Radiant Industries for Kaleidos transportable microreactors, deliveries before decade-end, including Radiant prepayments; value/volume undisclosed. (8-K, 2026-09-09)
• 2026-08-04/06: Q2 2026 print (8-K + 10-Q). Revenue $176.1M vs $154.5M Q2 2025 (+14%); GAAP net income $16.8M vs $28.9M (-42%), pressured by advanced-technology spend and a $17.2M non-cash RSU-reclassification charge. Technical Solutions segment swung to a $1.7M gross loss (from a $3.2M profit) as DOE signaled it will not further option the HALEU Operation Contract. FY2026 guidance repeated at $450-500M revenue / $350-500M capex. Backlog $4.5B. Same day (8/6): a definitive LEU/HALEU contract with X-energy supporting Xe-100 SMR and TRISO-X fuel deployments, including X-energy prepayments; value, volume, and duration undisclosed.
• 2026-06-30: the $900M DOE HALEU Production Contract task order was DEFINITIZED -- firm-fixed-price, milestone-paid, $1.07B including options, deliverable 1 MT of commercial HALEU UF6 by March 2032. The government-co-investment leg of the expansion thesis is now CONTRACTUAL, not aspirational. The market shrugged, because the toll is collected in 2032 -- a duration mismatch, not a thesis miss. (Source: 2026-07-13 dilution defense audit / 2026-07-14 handoff; resolves the definitization watch-item below.)
• 2026-06-18: Oklo Letter of Intent -- HALEU supply for up to five Aurora powerhouses supporting Oklo's planned 1.2 GW southern-Ohio Clean Energy Campus; deliveries scheduled to begin 2029; LOI anticipates a further definitive contract and possible Oklo prepayments. No definitive agreement disclosed since. (8-K, 2026-06-18)
• 2026-05-05/06: Q1 2026 print (8-K + 10-Q). Revenue $76.7M (+5% YoY); GAAP net income $10.0M (-63% YoY) driven by $18.9M advanced technology costs (pre-capitalization expansion spend) and a lapped one-time debt-extinguishment gain; adjusted net income $23.5M. FY2026 revenue guidance RAISED to $450-500M -- explicitly assuming the $900M DOE task order finalizes. Backlog $3.9B (of which $2.4B contingent on new capacity). Disclosed: FY2027 DOE budget proposal excludes HALEU cascade funding (Option 1a funded only through June 30, 2026).
• 2026-04: Geiger Brothers selected as Piketon construction contractor (time-and-materials, performance period through January 2031; prior site experience on the existing HALEU cascade and the 2013 demonstration cascade).
• 2026-03: Palantir manufacturing-optimization partnership (~$300M potential cost savings identified, early-stage figure); Oklo joint-venture exploration for HALEU deconversion services co-located at Piketon.
• 2026-02-09: Fluor Federal Services EPC contract signed for the Piketon expansion (time-and-materials; cancellation fee $24M declining $2M/month).
• 2026-05-13: T3 layer established -- first-ever T3 tranche position. Nuclear processing layer now operational in the portfolio.
• 2026-05-22: T3 scaling add.
• Next dated: Q3 2026 earnings date not yet announced as of 2026-09-14 -- monitor IR calendar; update when scheduled.

Note: LEU has limited public news cadence outside earnings and DOE contract milestones. Absence of headlines is normal, not bearish.

Risks / What would break the thesis

• HALEU cascade funding continuity -- the Q2 print answered part of this, unfavorably. DOE amended the HALEU Operation Contract on 2026-06-30, splitting the former Option 1b into a 3-month Option 1b ($15.0M, maintenance and storage only, no production) and a 21-month Option 1c whose resolution is not yet disclosed. Option 1a remained funded at $108.2M through June 30. The FY2027 DOE budget proposal excludes cascade-operation funding, and DOE has separately stated it does not currently intend to exercise further options under this contract -- affecting the ~$0.8B Technical Solutions segment backlog tied to it. Technical Solutions gross profit flipped from a $3.2M profit (Q2 2025) to a $1.7M gross loss (Q2 2026) over the same window. The $900M/$1.07B HALEU Production Contract (definitized 2026-06-30) is a separate, successor agreement and is unaffected -- but it does not retroactively fund the legacy cascade's near-term operating costs. Open: Option 1c's outcome.
• ~~DATED: $900M HALEU Production task order fails to definitize~~ RESOLVED 2026-06-30: DEFINITIZED (firm-fixed-price, milestone-paid, $1.07B with options, 1 MT commercial HALEU UF6 by March 2032). The risk did not fire; the guidance assumption is now contractual. Residual risk shifts to EXECUTION (milestone delivery on a 2032 horizon) and to FY2027+ appropriations for anything beyond the definitized scope.
• TENEX supply dependency -- more than one-half of LEU expected to be delivered to customers through 2027 is sourced from TENEX (Rosatom) under DOE waivers (third waiver application still pending) and per-shipment Russian export licenses with no certainty of future issuance; January 2025 Treasury sanctions already forced a payment-delay arrangement. The Russian ban is a moat for HALEU and a supply risk for the LEU trading segment at the same time.
• Dilution -- share count grew 18.1% in FY2025 via ATM. Convertible notes, two tranches at filed conversion rates (verified 2026-07-13 dilution defense audit; corrects this page's prior "~12.4M shares" figure, a 63% overstatement): Nov-2024 $402.5M / 2.25% / due 2030 at a $97.50 conversion price (~4.13M sh -- ITM only because the stock doubled from the ~$78 it was priced against; textbook above-cost tax) + Aug-2025 $805M / 0% / due 2032 at $229.62 (~3.51M sh, currently OTM) = ~7.63M shares on full conversion. NO capped call on either tranche (confirmed via EDGAR full-text search) -- nothing caps a rally, but above $229.62 both tranches convert. CORRECTION 2026-09-14: the $1.0B Nov-2025 ATM was not idle. It issued 278,114 shares for $55.0M gross ($54.2M net) in Q2 2026, leaving ~$554.5M of shelf capacity as of 2026-06-30 (10-Q, 2026-08-06) -- this page's prior "drawn $0" claim was accurate only through Q1 2026 and went stale. On 2026-09-10/11 Centrus separately closed a ~$500M underwritten offering (500,000 shares + pre-funded warrants + four series of common warrants on ~6.99M further shares struck $226.86 to $362.98, ~$2B of exercise proceeds if all exercised; holders capped at 4.99% ownership). The ~$500M gross approaches the ~$554.5M of shelf capacity remaining at 2026-06-30, so further shelf headroom is limited absent a new registration (any Q3 2026 ATM before the raise is not yet disclosed). Stacked with the converts, full dilution on a re-rate above the highest warrant strike runs to roughly 36.8M shares from the ~19.7M post-offering base, approximately +87%. Invalidation criterion: an equity raise that funds operations rather than capacity. The September 2026 offering's stated use of proceeds is general working capital / corporate purposes and does not name Piketon; the criterion is therefore neither tripped nor cleared by this filing alone. Resolution awaits (1) the FY2026 10-K's FY2027 capital-deployment guidance (due ~Feb 2027) and (2) whether the disclosed ~$115-125M domestic-manufacturing-supplier acquisition (advanced discussions as of 2026-09-11, target ~$160M FY2025 revenue) is signed or abandoned.
• Uranium price collapse removes urgency for domestic fuel supply investment and pressures all upstream names including LEU
• Competitor HALEU license approved -- if another US entity (e.g., Urenco USA, BWXT advanced enrichment) clears NRC HALEU authorization, the monopoly thesis is diluted (timeline: years, not imminent, but the structural moat is regulatory not technological)
• Expansion execution -- the multi-billion-dollar Piketon buildout is explicitly contingent on "securing substantial public and private investment"; combined backlog reached $4.5B as of 2026-06-30 (LEU segment $3.7B, of which ~$3.0B is contingent on capacity that does not exist yet and $2.4B sits under definitive agreements); Centrus expects to complete its first new centrifuge at Oak Ridge by year-end 2026, with first centrifuges from Oak Ridge expected online in Ohio in 2029

Triggers

Entry trigger: SATISFIED 2026-05-13. Position established.

Scaling triggers (refreshed 2026-06-10): The entry-add band was refreshed 2026-06-10; band details are withheld while a staged accumulation plan is active. Non-space sector, so the position sits outside the space-cluster sector cap.

Dated watch-items (status as of 2026-09-14): 1. June 30, 2026 -- HALEU cascade funding boundary: RESOLVED UNFAVORABLY for the legacy contract. DOE split the residual option into a 3-month maintenance-only Option 1b ($15.0M) and a 21-month Option 1c whose outcome remains undisclosed; DOE has separately stated it does not currently intend to exercise further options, and the FY2027 budget proposal excludes cascade funding. Does not touch the separate, definitized $900M/$1.07B production contract (row 2). 2. $900M HALEU Production task order: DEFINITIZED 2026-06-30. Firm-fixed-price, milestone-paid, $1.07B with options, 1 MT commercial HALEU UF6 by March 2032. Watch shifts to milestone execution. 3. The "idle-ATM" premise fired -- but as a structured offering, not the ATM. The Piketon-buildout funding question this page previously framed as a 2027 event resolved 2026-09-10/11, roughly 14 months early, via a ~$500M stock-plus-warrant offering. See Risks / Dilution. 4. NEW: capacity-vs-operations resolution -- two dated checkpoints. (a) The FY2026 10-K's FY2027 capital-deployment guidance, due ~Feb 2027, is the primary resolution point for whether the September 2026 raise funded capacity or operations. (b) Whether the disclosed ~$115-125M domestic-manufacturing-supplier acquisition (advanced discussions as of 2026-09-11) is signed or abandoned is a nearer-term tell pointing toward capacity if signed.

Do not trim: STCG-locked until ~May 2027. Also a structural conviction hold -- the thesis is supply-chain completion, not a momentum trade.

Watch items post-entry: - HALEU cascade funding boundary headlines (June 30, 2026) and $900M task-order definitization -- see Dated watch-items above - Shares outstanding trend (dilution signal; $1.0B shelf effective November 2025, unused as of the Q1 10-Q) - Any new HALEU license application by competitor (monitor NRC ADAMS docket) - Q2 2026 earnings print: August 4, 2026 (verified 2026-06-10)

External authoritative sources

• Centrus Energy IR page
• Latest 10-K (FY2025) -- SEC EDGAR
• DOE HALEU Operations Contract announcement
• StockAnalysis LEU forecast and analyst targets
• Prohibiting Russian Uranium Imports Act -- DOE summary

Open questions / hypotheses

1. ANSWERED 2026-06-10: Q2 2026 earnings date is August 4, 2026 (verified; beta 1.44 remains below the >3 threshold).
2. ANSWERED 2026-05 (Q1 10-Q): the cascade is operating under HOC Option 1a, funded $108.2M through June 30, 2026; HALEU Operation Contract revenue rose $9.8M YoY in Q1. Open residue: Phase 2 costs incurred after November 2024 remain undefinitized (no fee recorded) -- watch for definitization.
3. PARTIALLY ANSWERED: the Piketon expansion targets at least 12 metric tons/year of HALEU capacity (Geiger 8-K). Still open: current demonstration-cascade production rate (only the cumulative 900 kg Phase 2 figure is disclosed) and the capacity gap vs. projected SMR demand through 2030.
4. Is Urenco USA or any other entity in active NRC pre-application for HALEU authorization? If yes, moat timeline shortens. (Still open; monitor ADAMS docket.)
5. ANSWERED 2026-08-06 (Q2 10-Q), PARTIALLY: cascade operation does NOT continue under the definitized production order. DOE split the legacy Option 1b into a 3-month maintenance-only extension ($15.0M) and a 21-month Option 1c, and has separately stated it does not currently intend to exercise further HALEU Operation Contract options; the FY2027 budget proposal excludes cascade funding. Residual open question: Option 1c's outcome (undisclosed in any atom through 2026-09-14).
6. ANSWERED 2026-06-30: the $900M HALEU Production task order DEFINITIZED -- firm-fixed-price, milestone-paid, $1.07B with options, 1 MT commercial HALEU UF6 by March 2032.
7. NEW: Refresh the analyst consensus (the $278 / Strong Buy figure is a 2026-05-14 snapshot; price has since traded ~$148).
8. NEW: Is the disclosed ~$115-125M domestic-manufacturing-supplier acquisition (advanced discussions as of 2026-09-11) signed, or abandoned? Target identity undisclosed.
9. NEW: Has the Oklo Letter of Intent (2026-06-18) converted to a definitive supply agreement? Not disclosed as of the 2026-09-14 synthesis.
10. NEW: Dollar value, volumes, and duration for all three named private HALEU offtake agreements (Oklo, X-energy, Radiant) remain undisclosed -- watch for a future filing that quantifies any of them.

Decision log

• 2026-05-12: Page created.
• 2026-05-13: T3 layer established -- first-ever T3 tranche.
• 2026-05-14: Page moved from watchlist/ to stocks/. Status: watchlist → hold. Reflects held-position state.
• 2026-07-14: Converts figure corrected -- this page had claimed the convertible notes create "~12.4M shares"; the filed conversion rates give ~7.63M (Nov-2024 tranche ~4.13M @ $97.50 + Aug-2025 tranche ~3.51M @ $229.62). A 63% overstatement carried on the book's purest toll booth since the page's creation. Also recorded: the $900M DOE HALEU Production task order DEFINITIZED 2026-06-30 ($1.07B with options, 1 MT by March 2032) -- resolves dated watch-item 2; cascade-funding-boundary resolution detail deferred to the Aug 4 Q2 print.
• 2026-06-10: Wiki refreshed against the Q1 2026 filing arc (FY2025 10-K through Q1 10-Q; thesis state 2026-05-18). "DOE relationship de-risks near-term revenue" retired as a thesis line -- replaced by two dated execution risks (June 30, 2026 HALEU cascade funding boundary; $900M HALEU Production task-order definitization). Entry-add band refreshed and fenced private while the staged accumulation plan is active.
• 2026-09-14: Wiki refreshed against the re-synthesized thesis state (11 atoms; data/company_thesis_states/LEU.json) and the annotated dilution re-audit (project/research/leu_dilution_reaudit_2026-09-11.md). Corrected a factual error: this page previously stated the $1.0B Nov-2025 ATM had "drawn $0" through H1 2026; it in fact issued 278,114 shares for $55.0M gross in Q2 2026. Added: Q2 2026 results, the September 2026 ~$500M stock-plus-warrant offering, three private HALEU offtake agreements (Oklo LOI 6/18, X-energy definitive 8/6, Radiant definitive 9/9), the ~$115-125M supplier-acquisition-in-discussions, and DOE's disclosed intent not to further option the legacy HALEU Operation Contract. The dilution invalidation criterion ("an equity raise that funds operations rather than capacity") is not tripped or cleared by the September raise alone; two dated checkpoints now track its resolution (~Feb 2027 FY2027 capex guidance; the acquisition's signed/abandoned outcome).